McCullough Fiona, Cheung Janice, Miller Laura J
School of Biosciences, University of Nottingham, Nottingham LE12 5RD, UK.
Department of Dietetics and Nutrition, Nottingham University Hospitals NHS Trust, Nottingham NG5 1PB, UK.
Nutrients. 2025 Sep 16;17(18):2973. doi: 10.3390/nu17182973.
Gut health is often disrupted in adults with haematological malignancies (HMs) receiving chemotherapy and haematopoietic stem cell transplantation (HCT). Microbial diversity is reduced, and both infection risk and inflammation increased. The role of dietary fibre in enhancing gut health, immune regulation, reducing complications, and improving clinical outcomes for people with HMs shows promise but the extent of their role remains unclear. This systematic review evaluated the role of dietary fibre supplementation in adults with HMs undergoing HCT on gut health, immune function, and gastrointestinal health. This included assessment of differences between fibre types. A systematic search of PubMed and EMBASE was conducted following PRISMA guidelines, independently by two reviewers. Study quality was assessed using the Newcastle-Ottawa scale (NOS). Of the 5023 studies after de-duplication, 63 remained after abstract and title screening, 59 studies were full-text screened, 56 studies were excluded due to language ( = 6), wrong intervention ( = 25), wrong population ( = 4), or reporting on unrelated outcomes ( = 21), and 3 studies met all inclusion criteria. Interventions included fructooligosaccharides (FOS), resistant starch (RS), and a glutamine, fibre, and oligosaccharide (GFO) prebiotic blend. Despite heterogeneity in measured outcomes, positive impacts on gut health, immune function, and gastrointestinal health were shown. Fibre supplementation represents a promising adjunctive strategy to improve clinical outcomes in adults with HMs undergoing HCT, by improving microbial diversity, increasing short-chain fatty acid (SCFA) production, and reducing incidence of acute GVHD. Further research is needed to establish specific recommendations for fibre in the nutritional management of patients with HM.
接受化疗和造血干细胞移植(HCT)的血液系统恶性肿瘤(HM)成年患者的肠道健康常常受到破坏。微生物多样性降低,感染风险和炎症均增加。膳食纤维在增强HM患者的肠道健康、免疫调节、减少并发症及改善临床结局方面显示出前景,但它们的作用程度仍不明确。本系统评价评估了膳食纤维补充剂对接受HCT的HM成年患者肠道健康、免疫功能和胃肠道健康的作用。这包括评估不同类型纤维之间的差异。两名研究者按照PRISMA指南独立对PubMed和EMBASE进行了系统检索。使用纽卡斯尔-渥太华量表(NOS)评估研究质量。在去除重复后的5023项研究中,经过摘要和标题筛选后剩下63项,59项研究进行了全文筛选,56项研究因语言问题(=6)、干预错误(=25)、人群错误(=4)或报告不相关结局(=21)而被排除,3项研究符合所有纳入标准。干预措施包括低聚果糖(FOS)、抗性淀粉(RS)以及一种谷氨酰胺、纤维和低聚糖(GFO)益生元混合物。尽管测量结果存在异质性,但仍显示出对肠道健康、免疫功能和胃肠道健康有积极影响。补充纤维是一种有前景的辅助策略,可通过改善微生物多样性、增加短链脂肪酸(SCFA)生成及降低急性移植物抗宿主病(GVHD)发生率来改善接受HCT的HM成年患者的临床结局。需要进一步研究以确定HM患者营养管理中纤维的具体建议。